FDA "Lock-Ups" Aimed At Cutting Down Surprises
This article was originally published in RPM Report
Executive Summary
FDA plans to "lock up" reporters before major drug safety announcements in order to brief them more thoroughly and give them access to agency experts. FDA is working on a policy paper related to its external relations efforts.
You may also be interested in...
Benlysta Approved: FDA's Silence is Deafening
FDA’s approval of a new lupus therapy had all the elements of a big story to put the agency in a favorable light. But FDA took a decidedly low key approach to the decision, saying it didn’t want to “overhype” the product. That may be a missed opportunity for FDA’s image with key legislators—but it underscores the sense of ambivalence FDA had towards the product all along.
FDA's Media Frenzy
The Food & Drug Administration is trying to reverse its negative image tide by adopting a more proactive relationship with the news media. Over one five-week period alone, FDA held almost a dozen media teleconference calls on drug- or biologic-related issues. The extra attention is either good or bad news for manufacturers, depending on the subject of the media briefing.
FDA's Media Frenzy
The Food & Drug Administration is trying to reverse its negative image tide by adopting a more proactive relationship with the news media. Over one five-week period alone, FDA held almost a dozen media teleconference calls on drug- or biologic-related issues. The extra attention is either good or bad news for manufacturers, depending on the subject of the media briefing.